XTAI
1783
Market cap124mUSD
Dec 05, Last price
43.30TWD
1D
0.58%
1Q
0.23%
Jan 2017
111.01%
IPO
110.09%
Name
Maxigen Biotech Inc
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Maxigen Biotech Inc. engages in the development, manufacture, and marketing of biomedical and skincare products in Taiwan and internationally. The company offers Formagraft, a bone graft substitute; Formasetin, a bone void filler; and intra-articular injections under the ArtiAid, ArtiAid Plus, and ArtiBest names for use in orthopedic area. It also provides Foramic, a bone substitute granule; MaxiBone, a calcium phosphate ceramic; and GingivAid, a collagen dental grafts for use in orthopedic and dental areas. In addition, the company offers FormaAid, a collagen membrane; and E-TECH DENTISTAR II sterilizer and disinfectant for use in dental area, as well as HealiAid, a collagen wound dressing product for use in dental and wound dressing area. Further, it provides ophthalmic viscoelastic device under the ViscAid, PreviscAid, and BiVisc names; and Formaderm, a dermal filler injection for use in plastic surgery. Additionally, the company offers skincare products, including face, neck, body, limbs, and other masks; and make up remover, cleansing, exfoliating, toner, essence, men's care, sunscreen, body care, hand/foot care, and special care products. Maxigen Biotech Inc. was founded in 1998 and is based in Taoyuan City, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||